Option chain shows key data for AN2 Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AN2 Therapeutics.

AN2 Therapeutics (NASDAQ:ANTX) Stock, Option Chain

AN2 Therapeutics

Anthem

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

LEVI, Levi Strauss

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANTX

CNET

EONR

FLUX

GRFX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

KXIN

LEVI

MLGO

MYNA

NDRA

SNGX

VCIG

WHLR

Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket

Earnings

Earnings Beats

Large Cap

Penny Stocks

Small Cap

Analyst Ratings

ARCT

FULC

ILMN

AN2 Therapeutics (NASDAQ: ANTX), a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.

AN2 Therapeutics Plunges 66% in a Month: Here&#39;s Why

penny stocks tips 1

Long Ideas

Insider Trades

RPHM

Citizens And 2 Other Penny Stocks Insiders Are Buying

AN2 Therapeutics Inc

Press Releases

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

CalciMedica

Cara Therapeutics

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cocrystal Pharma

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Grace Therapeutics

Impact BioMedical

IGC Pharma

Ikena Oncology

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Scilex Holding

SCYNEXIS

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

VYNE Therapeutics

Citizens Capital Markets

JMP Securities

Evercore ISI Group

SVB Leerink

Oppenheimer

Comments

AN2 Therapeutics

AN2 Therapeutics (ANTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga